---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-021365"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:25:41.201999+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics loses audit committee compliance after Chairman Ronald Hunt resigns

## Summary
- Chairman Ronald Hunt resigned Feb 14, 2025, ending 9+ year tenure; no dispute with board.
- Vacancy on Audit Committee triggers non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).
- Company notified Nasdaq same day; faces potential delisting if compliance not restored.
- Hunt also served on compensation, nominating, and governance committees.

## SEC filing metadata
- accession: 0000950170-25-021365
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025021365/0000950170-25-021365-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025021365/itrm-20250214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-021365
- JSON: https://secwatch.observer/filing/0000950170-25-021365.json
- Plain text: https://secwatch.observer/filing/0000950170-25-021365.txt

## Source-grounded claims
- claim_id: 2a95374ecc73e2886c9b5fdd8f790af6acac3e13
  claim: Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).
  evidence_excerpt: February 14, 2025, Iterum Therapeutics plc (the “Company”), notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025021365/0000950170-25-021365-index.htm
- claim_id: e69c15f68f
  claim: Ronald Hunt resigned as Chairman and director at Iterum Therapeutics plc.
  evidence_excerpt: On February 14, 2025, Ronald Hunt, Chairman and director of the Company, notified the Company of his resignation as Chairman and director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025021365/0000950170-25-021365-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.